Krystal Biotech develops in vivo gene therapies for dermatological conditions and has transitioned into commercial revenue generation. The company sits in the biological products segment and now reports material quarterly sales and GAAP diluted EPS, moving beyond purely development-stage metrics.
The financial picture shows clear scale-up: quarterly revenue rose from $8.56 million in CY2023Q3 to $119.22 million in CY2026Q2. GAAP diluted EPS turned positive and has remained positive through recent quarters, reaching as high as $2.66 in CY2025Q3 and recording $1.83 and $1.79 in CY2026Q1 and CY2026Q2 respectively. Year-over-year growth remains positive — 31.95% in CY2026Q1 and 24.14% in CY2026Q2 — but both revenue and EPS acceleration flags are false, indicating growth has expanded but is not currently accelerating.
The revenue and profitability progress places Krystal within the Biotech Therapeutics theme as a commercial-stage growth name that has outperformed the market: the stock shows a 12-month excess return versus the S&P 500 of 127.2% and a three-month excess return of 18.6%. Technicals confirm a sustained uptrend, institutional reporting is broad with 571 institutions disclosing positions, and the company meets several leader-selection gates for growth, trend and ownership.
Why now
Sequential quarterly revenue has scaled to $119.2 million with sustained GAAP profits and the stock sits above its 50- and 200-day averages while outperforming the S&P 500; this combination of commercial traction, positive GAAP EPS and a confirmed uptrend makes the name timely to watch within dermatology-focused biotech, even though no fresh technical entry is present.
The setup
Last close was $371.47 (as of 2026-09-03), above the 50-day SMA of $349.79 and the 200-day SMA of $289.57, with the 9-day EMA at $359.50 and the 21-day EMA at $350.88. Seven of seven trend checks passed and the Weinstein stage is Stage 2 — continuation. RSI sits at 63.59. Entry-readiness is listed as watch, not actionable; there is no verified fresh breakout or 9/21-day EMA add setup and the current price sits about 3.3% above the 9-day EMA and 5.9% above the 21-day EMA.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (8 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $7.87 (+15%) · FY'27E $9.40 (+19%) — 8 analysts
Risks
Revenue growth has slowed from the initial scaling jump and acceleration metrics are false, so top-line expansion could plateau; GAAP diluted EPS has been volatile quarter to quarter, dropping from $2.66 in CY2025Q3 to the high $1.70s in early 2026, which creates earnings risk; and the technical picture, while in an uptrend, shows no fresh entry signal, meaning the stock could reverse before presenting a constructive new setup.
Framework fit
CANSLIM
6/7- CCurrent quarterly GAAP EPS growth ≥ 25%+39%✓
- AAnnual GAAP EPS growth ≥ 25%+128%✓
- NNew highs — within 15% of 52-week high-1.77%✓
- SSupply/demand — up-day volume leads0.75x✕
- LLeader — outperforming the S&P 500+29% 6m✓
- IInstitutional sponsorshipmodel score 8/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.